Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury

Free Radical Biology and Medicine

Volumn 74, Issue , 2014, Pages 210-221

  Jansová, Hana ^a   Macháček, Miloslav ^a   Wang, Qin ^b   Hašková, Pavlína ^a   Jirkovská, Anna ^a   Potůčková, Eliška ^a   Kielar, Filip ^b   Franz, Katherine J ^b   Šimůnek, Tomáš ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b DUKE UNIVERSITY   (United States)

Author keywords

BSIH; Deferasirox; Free radicals; ICL670A; Iron chelation; Prochelator; Salicylaldehyde isonicotinoyl hydrazone

Indexed keywords

4 [5 [2 [(4 BORONOBENZYL)OXY]PHENYL] 3 (2 HYDROXY PHENYL) 1H 1,2,4 TRIAZOL 1 YL]BENZOIC ACID; CHELATING AGENT; CYTOPROTECTIVE AGENT; DEFERASIROX; FERRIC ION; IRON CHELATING AGENT; METHYL 4 [3 (2 HYDROXY PHENYL) 5 [2 [[4 (4,4,5,5 TETRAMETHYL 1,2,3 DIOXOBOROLAN 2 YL)BENZYL]OXY]PHENYL] 1H 1,2,4 TRIAZOL 1 YL]BENZOATE; N' [1 (2 HYDROXYPHENYL)ETHYLIDEN]ISONICOTINOHYDRAZIDE; N' [2 (3A,5,5 TRIMETHYLHEXAHYDRO 4,6 METHANOBENZO[D][1,2,3]DIOXABOROLAN 2 YL)BENZYLIDENE]ISONICOTINOHYDRAZIDE; N' [2 (4,4,5,5 TETRAMETHYL[1,2,3]DIOXABOROLAN 2 YL)BENZYLIDENE ISONICOTINOHYDRAZ; PROCHELATOR DERIVATIVE; SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; UNCLASSIFIED DRUG; [1 [2 [[4 (4,4,5,5 TETRAMETHYL 1,2,3 DIOXOBOROLAN 2 YL)BENZYL]OXY]PHENYL]ETHYLIDENE]ISONICOTINOHYDRAZIDE; (ISONICOTINIC ACID (2-(4,4,5,5-TETRAMETHYL-(1,3,2)DIOXABOROLAN-2-YL)BENZYLIDENE)HYDRAZIDE); ALDEHYDE; BENZOIC ACID DERIVATIVE; BORON DERIVATIVE; BORONIC ACID DERIVATIVE; HYDRAZONE DERIVATIVE; HYDROGEN PEROXIDE; IRON; ISONICOTINIC ACID; N'-(1-(2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYLOXY)PHENYL)ETHYLIDENE)ISONICOTINOHYDRAZIDE; SEMICARBAZONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; EMBRYO; FIBROBLAST; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON CHELATION; KERATINOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; APOPTOSIS; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; HEART MITOCHONDRION; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ALDEHYDES; ANIMALS; APOPTOSIS; BENZOATES; BORON COMPOUNDS; BORONIC ACIDS; CELL LINE; CELL MEMBRANE PERMEABILITY; CYTOPROTECTION; HYDRAZONES; HYDROGEN PEROXIDE; IRON; IRON CHELATING AGENTS; ISONICOTINIC ACIDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; RATS, WISTAR; SEMICARBAZONES; TRIAZOLES;

EID: 84905197686     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.06.019     Document Type: Article

References (51)

1. N.C. Andrews, and P.J. Schmidt Iron homeostasis Annu. Rev. Physiol. 69 2007 69 85 (Pubitemid 46457636)
2. B. Halliwell, and J.M.C. Gutteridge Free Radicals in Biology and Medicine 2007 Oxford Univ. Press Oxford/New York
3. K. Jomova, and M. Valko Advances in metal-induced oxidative stress and human disease Toxicology 283 2011 65 87
4. D.B. Kell Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples Arch. Toxicol. 84 2010 825 889
5. P. Mladenka, T. Simunek, M. Hubl, and R. Hrdina The role of reactive oxygen and nitrogen species in cellular iron metabolism Free Radic. Res. 40 2006 263 272 (Pubitemid 43245441)
6. D.W. Reif Ferritin as a source of iron for oxidative damage Free Radic. Biol. Med. 12 1992 417 427
7. A. Terman, and U.T. Brunk Oxidative stress, accumulation of biological 'garbage', and aging Antioxid. Redox Signaling 8 2006 197 204 (Pubitemid 43324546)
8. K.K. Griendling, and G.A. FitzGerald Oxidative stress and cardiovascular injury. Part I. Basic mechanisms and in vivo monitoring of ROS Circulation 108 2003 1912 1916 (Pubitemid 37296532)
9. C.H. Hennekens, J.E. Buring, J.E. Manson, M. Stampfer, B. Rosner, N.R. Cook, C. Belanger, F. LaMotte, J.M. Gaziano, P.M. Ridker, W. Willett, and R. Peto Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease N. Engl. J. Med. 334 1996 1145 1149 (Pubitemid 26137972)
10. R. Lee, M. Margaritis, K.M. Channon, and C. Antoniades Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations Curr. Med. Chem. 19 2012 2504 2520
11. K.J. Franz Clawing back: broadening the notion of metal chelators in medicine Curr. Opin. Chem. Biol. 17 2013 143 149
12. J.B. Galey Recent advances in the design of iron chelators against oxidative damage Mini Rev. Med. Chem. 1 2001 233 242
13. D.S. Kalinowski, and D.R. Richardson The evolution of iron chelators for the treatment of iron overload disease and cancer Pharmacol. Rev. 57 2005 547 583 (Pubitemid 43036441)
14. P. Dobsak, J. Siegelova, J.E. Wolf, L. Rochette, J.C. Eicher, J. Vasku, S. Kuchtickova, and M. Horky Prevention of apoptosis by deferoxamine during 4 hours of cold cardioplegia and reperfusion: in vitro study of isolated working rat heart model Pathophysiology 9 2002 27
15. W. Chan, A.J. Taylor, A.H. Ellims, L. Lefkovits, C. Wong, B.A. Kingwell, A. Natoli, K.D. Croft, T. Mori, D.M. Kaye, A.M. Dart, and S.J. Duffy Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction Circ. Cardiovasc. Interv. 5 2012 270 278
16. P. Bendova, E. Mackova, P. Haskova, A. Vavrova, E. Jirkovsky, M. Sterba, O. Popelova, D.S. Kalinowski, P. Kovarikova, K. Vavrova, D.R. Richardson, and T. Simunek Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury Chem. Res. Toxicol. 23 2010 1105 1114
17. P. Haskova, L. Koubkova, A. Vavrova, E. Mackova, K. Hruskova, P. Kovarikova, K. Vavrova, and T. Simunek Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity Toxicology 289 2011 122 131
18. P. Haskova, P. Kovarikova, L. Koubkova, A. Vavrova, E. Mackova, and T. Simunek Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity Free Radic. Biol. Med. 50 2011 537 549
19. M. Horackova, P. Ponka, and Z. Byczko The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes Cardiovasc. Res. 47 2000 529 536 (Pubitemid 30646074)
20. T. Simunek, C. Boer, R.A. Bouwman, R. Vlasblom, A.M. Versteilen, M. Sterba, V. Gersl, R. Hrdina, P. Ponka, J.J. de Lange, W.J. Paulus, and R.J. Musters SIH - a novel lipophilic iron chelator - protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death J. Mol. Cell. Cardiol. 39 2005 345 354 (Pubitemid 40995024)
21. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol. Rep. 61 2009 154 171
22. M. Sterba, O. Popelová, T. Simůnek, Y. Mazurová, A. Potácová, M. Adamcová, I. Guncová, H. Kaiserová, V. Palicka, P. Ponka, and V. Gersl Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH) Toxicology 235 2007 150 166 (Pubitemid 46734545)
23. L.K. Charkoudian, D.M. Pham, and K.J. Franz A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation J. Am. Chem. Soc. 128 2006 12424 12425 (Pubitemid 44476626)
24. L.K. Charkoudian, T. Dentchev, N. Lukinova, N. Wolkow, J.L. Dunaief, and K.J. Franz Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide J. Inorg. Biochem. 102 2008 2130 2135
25. L.K. Charkoudian, D.M. Pham, A.M. Kwon, A.D. Vangeloff, and K.J. Franz Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress Dalton Trans. 43 2007 5031 5042 (Pubitemid 350015426)
26. K. Hruskova, P. Kovarikova, P. Bendova, P. Haskova, E. Mackova, J. Stariat, A. Vavrova, K. Vavrova, and T. Simunek Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis Chem. Res. Toxicol. 24 2011 290 302
27. F. Kielar, Q. Wang, P.D. Boyle, and K.J. Franz A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding Inorg. Chim. Acta 393 2012 294 303
28. J.T. Edward, M. Gauthier, F.L. Chubb, and P. Ponka Synthesis of new acylhydrazones as iron-chelating compounds J. Chem. Eng. Data 33 1988 538 540
29. F. Kielar, M.E. Helsel, Q. Wang, and K.J. Franz Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation Metallomics 4 2012 899 909
30. B.W. Kimes, and B.L. Brandt Properties of a clonal muscle cell line from rat heart Exp. Cell Res. 98 1976 367 381
31. B.P. Espósito, S. Epsztejn, W. Breuer, and Z.I. Cabantchik A review of fluorescence methods for assessing labile iron in cells and biological fluids Anal. Biochem. 304 2002 1 18 (Pubitemid 34492837)
32. H. Glickstein, R.B. El, G. Link, W. Breuer, A.M. Konijn, C. Hershko, H. Nick, and Z.I. Cabantchik Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood 108 2006 3195 3203
33. G. Repetto, A. del Peso, and J.L. Zurita Neutral red uptake assay for the estimation of cell viability/cytotoxicity Nat. Protoc. 3 2008 1125 1131
34. N. Ke, X. Wang, X. Xu, and Y.A. Abassi The xCELLigence system for real-time and label-free monitoring of cell viability Methods Mol. Biol. 740 2011 33 43
35. U.T. Brunk, J. Neuzil, and J.W. Eaton Lysosomal involvement in apoptosis Redox Rep. 6 2001 91 97 (Pubitemid 32519816)
36. V. Berdoukas, A. Nord, S. Carson, M. Puliyel, T. Hofstra, J. Wood, and T.D. Coates Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age Am. J. Hematol. 88 2013 E283 E285
37. C. Hershko, G. Link, A.M. Konijn, and Z.I. Cabantchik Objectives and mechanism of iron chelation therapy Ann. N. Y. Acad. Sci. 1054 2005 124 135 (Pubitemid 43031017)
38. A.W. Nienhuis, and D.G. Nathan Pathophysiology and clinical manifestations of the beta-thalassemias Cold Spring Harbor Perspect. Med. 2 2012 a011726
39. Y. Cheng, X. Liu, S. Zhang, Y. Lin, J. Yang, and C. Zhang MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4 J. Mol. Cell. Cardiol. 47 2009 5 14
40. S.Y. Han, H.X. Li, X. Ma, K. Zhang, Z.Z. Ma, and P.F. Tu Protective effects of purified safflower extract on myocardial ischemia in vivo and in vitro Phytomedicine 16 2009 694 702
41. X. Luo, H. Cai, J. Ni, R. Bhindi, H.C. Lowe, C.N. Chesterman, and L.M. Khachigian c-Jun DNAzymes inhibit myocardial inflammation, ROS generation, infarct size, and improve cardiac function after ischemia-reperfusion injury Arterioscler. Thromb. Vasc. Biol. 29 2009 1836 1842
42. P.K. Mishra, N. Tyagi, U. Sen, S. Givvimani, and S.C. Tyagi H2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure Am. J. Physiol. Heart Circ. Physiol. 298 2010 H451 H456
43. A. Terman, T. Kurz, B. Gustafsson, and U.T. Brunk The involvement of lysosomes in myocardial aging and disease Curr. Cardiol. Rev. 4 2008 107 115
44. K. Roberg Relocalization of cathepsin D and cytochrome c early in apoptosis revealed by immunoelectron microscopy Lab. Invest. 81 2001 149 158 (Pubitemid 32176378)
45. L. Galluzzi, O. Kepp, C. Trojel-Hansen, and G. Kroemer Mitochondrial control of cellular life, stress, and death Circ. Res. 111 2012 1198 1207
46. R.M. Al-Rousan, S. Paturi, J.P. Laurino, S.K. Kakarla, A.K. Gutta, E.M. Walker, and E.R. Blough Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil Am. J. Hematol. 84 2009 565 570
47. T. Kurz, B. Gustafsson, and U.T. Brunk Intralysosomal iron chelation protects against oxidative stress-induced cellular damage FEBS J. 273 2006 3106 3117
48. N. Lukinova, J. Iacovelli, T. Dentchev, N. Wolkow, A. Hunter, D. Amado, G.S. Ying, J.R. Sparrow, and J.L. Dunaief Iron chelation protects the retinal pigment epithelial cell line ARPE-19 against cell death triggered by diverse stimuli Invest. Ophthalmol. Visual Sci. 50 2009 1440 1447
49. T. Simůnek, M. Sterba, O. Popelová, H. Kaiserová, M. Adamcová, M. Hroch, P. Hasková, P. Ponka, and V. Gersl Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone Br. J. Pharmacol. 155 2008 138 148
50. R. Galanello, A. Piga, D. Alberti, M.C. Rouan, H. Bigler, and R. Sechaud Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia J. Clin. Pharmacol. 43 2003 565 572 (Pubitemid 36613115)
51. I. Klimtova, T. Simunek, Y. Mazurova, J. Kaplanova, M. Sterba, R. Hrdina, V. Gersl, M. Adamcova, and P. Ponka A study of potential toxic effects after repeated 10-week administration of a new iron chelator - salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits Acta Med. (Hradec Kralove) 46 2003 163 170